Evogene Ltd. · NASDAQ:EVGN

Evogene — Q4 2024 Earnings Presentation

33 slides from Evogene's earnings presentation, Mar 6, 2025

1. Slide 1: Q4 2024 Earnings Call

   Exhibit 99.2 Q42024EARNINGSCALLOFERHAVIV|PRESIDENT&CEOMarch06,2025

2. Slide 2: Forward-looking statements

   Thispresentationcontains"forward-lookingstatements"relatingtofutureevents,andEvogeneLtd.(the“Company”),mayfromtimetotimemakeotherstatements,regardingouroutlookorexpectationsforfuturefinancialoroperatingresultsand/orothermattersregardingoraffectingusthatareconsidered“forward-lookingstatements”asdefin

3. Slide 3: Earnings Call Q4 2024 Agenda

   EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A3CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

4. Slide 4: CEO Update: New Chairman Nir Nimrodi

   44CEOUPDATEMr.NirNimrodihasservedasSpecialAdvisortotheEvogeneboardsince2020,andfromSeptember2022asaboardmember.Mr.Nimrodibrings25yearsofdiverseinternationalexperienceinbothstart-upsandlargeglobalbusinessesinthelifescience,pharmaceutical,andbiotechnologyindustries.Mr.NimrodiwastheChairmanandCEOofAcce

5. Slide 5: Agenda: Financial & Business Highlights

   EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A5CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

6. Slide 6: CEO Update: Financial Highlights - Revenues

   66CEOUPDATEFinancialHighlights:Intheyear2024,totalrevenuesreachedapproximately$8.5millioncomparedto$5.6millionintheyear2023.Theincreaseinrevenuesinyear2024,ismainlyduetoincreaseinAgPlenus'revenuesfromitscollaborationwithBayerandanincreaseinCasterra’sseedsales.InQ4of2024,totalrevenuesreachedapproxima

7. Slide 7: CEO Update: Financial Highlights - Expenses

   77CEOUPDATEFinancialHighlights:Intheyear2024,totalR&Dexpenseswereapproximately$16.6millioncomparedto$20.8millionintheyear2023.InQ4of2024,totalR&Dexpenseswereapproximately$3.4millioncomparedto$5.5millioninQ42023.ThesedecreasesaremainlyduetotheendofCanonic'sactivityinQ22024andadecreaseinBiomica'sandLa

8. Slide 8: CEO Update: Business Highlights 2024 to date

   88CEOUPDATEBusinessHighlights2024todate:EvogeneOct.2024,collaborationwithGoogleCloudtopioneergenerativeAIfoundationmodelfornovelsmallmoleculedesign.CasterraDuring2024,Casterradeliveredtoitspartner~215tonsofcastorseeds,~76tonsinQ42024.InFebruary2025Casterradeliveredtoitspartner~250tonsofcastorseeds.C

9. Slide 9: Business Highlights 2024 to date: Lavie Bio and AgPlenus

   BusinessHighlights2024todate:LavieBioFeb.2024,newcollaborationagreementwithSyngentatodiscoveranddevelopnovelbio-insecticides.July2024,ICLandLavieBioachievedasignificantmilestoneintheircollaboration,developingyield-increasingbio-stimulantsforrowcropsunderextremeweatherconditionsbyleveragingAItoidenti

10. Slide 10: Agenda: Evogene Overview

    EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A10CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

11. Slide 11: Our Vision and Mission

    OURVISIONPIONEERGROUNDBREAKINGLIFE-SCIENCEPRODUCTSROOTEDINMICROBES,SMALLMOLECULES,ANDGENOMICSDECODINGBIOLOGY11OURMISSIONWEMERGELIFE-SCIENCEWITHBIGDATAANDCUTTING-EDGEAITECHNOLOGIESTOEFFECTIVELYDISCOVERANDOPTIMIZEBREAKTHROUGHLIFE-SCIENCEBASEDPRODUCTS

12. Slide 12: Discovery & Optimization through 3 AI tech-engines

    DISCOVERY&OPTIMIZATIONWEDIRECTANDACCELERATELIFE-SCIENCEPRODUCTthrough3dedicatedAItech-enginesMICROBESGENETICELEMENTSSMALLMOLECULESTheResult:Promisingcandidatesaddressingmultipledevelopmentchallengestowardssuccessfullife-science-basedproducts.PROBABILITYOFSUCCESSTIMECOST12

13. Slide 13: A World of Opportunities for Our AI Tech Engines

    13SMALLMOLECULESGENETICELEMENTSMICROBESAWORLDOFOPPORTUNITIESFOROURAITECHENGINESAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESImprovedcropsAlternativefoodMedicalCannabisGenetherapyDiagnostics&precisionmedicineCelltherapyBiofuelFragrancesNaturalfoodcoloringNovelenzymesAGRICULTURE&FOODPHARMA&WELLNESSOT

14. Slide 14: Business Strategy

    14BUSINESSSTRATEGYCapturethevalueofourAItech-enginesthroughdiversecollaborativepartnershipstoacceleratelife-scienceproductdevelopmentPartneringwithexpertsinspecificfieldscomplementsourtechnology,enablinggroundbreakinginnovationsandfinancialgainsforEvogene.EVOGENEAITechEnginesNovelLife-ScienceProduct

15. Slide 15: Licensing & Collaboration Current Status

    AquacultureLicensingCollaborationImprovedcropsCropprotectionPharmaceuticalsMicrobialsforcropsTherapeuticmicrobials15LICENSING&COLLABORATION|CURRENTSTATUSFood-TechAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIES

16. Slide 16: Commercial & Financial Partners

    16GroupCOMMERCIAL&FINANCIALPARTNERSInvestment&CollaborationCollaborationInvestment&CollaborationCollaborationCollaborationInvestmentCollaborationCollaborationCollaborationCollaborationCollaboration

17. Slide 17: Looking into 2025-2026

    1717LOOKINGINTO2025-2026EvogeneFocusonenhancingChemPassAItech-engine’scompetitiveadvantageforthepharmamarketsegment(ex.-buildingfoundationmodelwithGoogleCloud).Engageincollaborationswithbio-techandacademiaforsmall-moleculedrugdiscovery,utilizingChemPassAI.ContinuethesupportanddevelopmentofMicroBoost

18. Slide 18: Drug Development Based on Small Molecules

    SMALLMOLECULESGENETICELEMENTSMICROBESAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESImprovedcropsAlternativefoodMedicalCannabisGenetherapyDiagnostics&precisionmedicineCelltherapyBiofuelFragrancesNaturalfoodcoloringNovelenzymesAGRICULTURE&FOODPHARMA&WELLNESSOTHERINDUSTRIESCropprotectionChemicalstimula

19. Slide 19: Why Pharma?

    TheChallenge:Discoveringtherightsmallmoleculeislikefindinganeedleinahaystack.TheRewards:Asolutionoffersthepotentialforsignificantfinancialimpact.TheAIRevolution:AIenablesthediscoveryandoptimizationofsmallmoleculecandidates,addressingmultipledevelopmentrequirementsforasuccessfuldrug.Thisapproachaddre

20. Slide 20: Multi-Million Agreements with Global Pharma

    MULTI-MILLIONAGREEMENTSWITHGLOBALPHARMA20

21. Slide 21: Why Evogene?

    WHYEVOGENE?MultidisciplinaryExpertiseIntegratingchemistry,biology,andAIforoptimizeddrugdiscoveryCollaborativePartnershipProvenabilitytoworkwithpartners,totranslatecomputationalpredictionsintoreal-worlddrugcandidatesAI-FirstApproachInternalcapabilitiestodevelopproprietymachinelearninganddeeplearninga

22. Slide 22: Discussions with Potential Partners

    22AUSTRALIACANADASOUTHKOREAISRAELGERMANYUKDISCUSSIONSWITHPOTENTIALPARTNERSUSA

23. Slide 23: Agenda: Subsidiaries' 2025 Targets

    EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A23CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

24. Slide 24: Casterra: Main Targets for 2025

    24Casterrafocusesondevelopingintegratedsolutionsforlarge-scalecastorbeanfarming,utilizingGeneRatorAItech-enginePoweredbyMaintargetsfor2025IncreasecastorseedsrevenueinAfricawithinitialsalesinBrazilandadditionalterritories.InitiatePOCtrialsforgrainfarmingforoilproduction,withatier1partnerinKenyaorBraz

25. Slide 25: Lavie Bio: Main Targets for 2025

    25LavieBio,agloballeaderindevelopingnextgenerationag-biologicalproducts,leveragingMicroBoostAItech-engineMaintargetsfor2025Engageinanewcollaborationagreementforfungicides(LAV311,LAV321).IncreaseYalos®revenuewithinitialsalesinsoybean.AchieveR&DmilestonesinICLcollaborationtowardcommercialagreement.Ach

26. Slide 26: AgPlenus: Main Targets for 2025

    AgPlenusspecializesindevelopingnovelandsustainablecropprotectionproducts,utilizingEvogene’sChemPassAItech-enginePoweredby26Maintargetsfor2025Achieve2ndmilestoneinCortevacollaborationagreement.ExecuteBayerherbicidecollaborationaccordingtoworkplan.Discoverandadvance2-3smallmolecules(hits)withnewMoAsin

27. Slide 27: Biomica: Main Targets for 2025

    27Biomicaspecializesindevelopingmicrobiome-basedtherapeuticsforhumanhealth,utilizingEvogene'sMicroBoostAItech-enginePoweredbyMaintargetsfor2025CompletePhase1studyinoncologyprogram;obtainfullresultsandadditionalsupportingclinicaldata.SubmitINDapplicationtotheUSFDAandobtainFDAapprovalforthePhase2study

28. Slide 28: Agenda: CFO Update

    EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A28CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

29. Slide 29: CFO Update: Consolidated Statements of Financial Position (Assets)

    CFO UPDATE evOgene CONSOLIDATED STATEMENTS OF FINANCIAL POSITION US. dollars in thousands CURRENT ASSETS: Cash and cash equivalents Short-term bank deposits Trade receivables Other receivables and prepaid expenses Deferred expenses related to issuance of warrants Inventories LONG-TERM ASSETS: Long-t

30. Slide 30: CFO Update: Liabilities and Shareholders' Equity

    CFO UPDATE December 31, December 31, 2024 2023 CURRENT LIABILITIES: Trade payables $ 1,228 $1,785 Employees and payroll accruals 1,869 2,537 Lease liability 589 853 Liabilities in respect of government grants 323 388 Deferred revenues and other advances 360 362 ‘Warrants and pre-funded warrants liab

31. Slide 31: Evogene Financial Performance 2024 and Q4 2024

    CFOUPDATEEvogeneFinancialPerformance2024andQ4202431

32. Slide 32: Agenda: Q&A

    EarningsCallQ42024AGENDANirNimrodi,NewChairmanFinancial&BusinessHighlightsEvogeneOverviewSubsidiaries’2025TargetsQ&A32CEOUpdate/ByOferHavivCFOUpdate/ByYaronEldad

33. Slide 33: Thank You

    ev gene = THANK YOU

Evogene — Q4 2024 Earnings Presentation on 6ix